|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.59 USD | -0.58% |
|
-9.13% | -12.97% |
| 02:00pm | Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 | MT |
| 12:54pm | Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating | MT |
April 5 (Reuters) - The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.
The health regulator is also reviewing another cancer cell therapy, Carvykti, from Johnson & Johnson and its partner Legend Biotech for use in less severely affected patients. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 146.4 USD | +0.15% | -2.08% | 352B | ||
| 45.08 USD | -0.49% | -4.21% | 8.24B | ||
| 44.6 USD | -0.55% | -9.13% | 90.92B | ||
| 4.515 USD | +6.11% | -3.01% | 219M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -12.97% | 90.92B | |
| +25.56% | 661B | |
| +26.74% | 566B | |
| -6.84% | 352B | |
| +18.76% | 332B | |
| +3.15% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.54% | 145B |
BRISTOL-MYERS SQUIBB COMPANY 
